(3'R,6R,8S)-6-(cycloocta-1,3,5,7-tetraenyl)-8-hydroxy-8-methyl-2-phenyl-7,8-dihydrospiro[[1,2,4]triazolo[1,2-a]pyridazine-5,3'-chroman]-1,3,4'(2H,6H)-trione

ID: ALA4530669

Chembl Id: CHEMBL4530669

PubChem CID: 155545987

Max Phase: Preclinical

Molecular Formula: C29H25N3O5

Molecular Weight: 495.54

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@]1(O)C[C@H](C2=C/C=C\C=C/C=C\2)[C@]2(COc3ccccc3C2=O)n2c(=O)n(-c3ccccc3)c(=O)n21

Standard InChI:  InChI=1S/C29H25N3O5/c1-28(36)18-23(20-12-6-3-2-4-7-13-20)29(19-37-24-17-11-10-16-22(24)25(29)33)32-27(35)30(26(34)31(28)32)21-14-8-5-9-15-21/h2-17,23,36H,18-19H2,1H3/b3-2-,4-2-,6-3-,7-4-,12-6-,13-7-,20-12+,20-13+/t23-,28+,29+/m1/s1

Standard InChI Key:  ORFFDQFWLRDVQN-XTARYGMQSA-N

Alternative Forms

  1. Parent:

    ALA4530669

    ---

Associated Targets(Human)

VKORC1 Tclin Vitamin k epoxide reductase complex subunit 1 isoform 1 (10 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 495.54Molecular Weight (Monoisotopic): 495.1794AlogP: 3.06#Rotatable Bonds: 2
Polar Surface Area: 95.46Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 12.97CX Basic pKa: CX LogP: 3.68CX LogD: 3.68
Aromatic Rings: 3Heavy Atoms: 37QED Weighted: 0.59Np Likeness Score: 0.58

References

1. Xing H, Houston SD, Chen X, Jin DY, Savage GP, Tie JK, Williams CM..  (2019)  Determining the necessity of phenyl ring π-character in warfarin.,  29  (15): [PMID:31147103] [10.1016/j.bmcl.2019.05.039]

Source